FDA Cleared Oral Fluid and Hair Drug Testing, So Why Can't Cleveland DOT Employers Use Them Yet?
If you manage a Cleveland workforce or a DOT-regulated fleet, recent federal actions may sound like an immediate change to workplace drug testing. They are not. The key distinction is simple: cleared does not mean authorized.
The FDA’s October 6, 2026 order removed a 510(k) premarket-notification barrier for certain clinical toxicology test systems. That is a device-regulation change. It does not, by itself, authorize a new testing method under U.S. Department of Transportation (DOT) rules, certify a laboratory, or change the DOT drug-testing panel.
For DOT employers, urine testing remains the current option. Non-DOT employers may consider oral fluid or hair testing under their own policies and applicable law, but should confirm the test, laboratory, and process suit their needs.

What the FDA order changed, and what it didn’t
The FDA’s October 6 final order expanded exemptions from 510(k) premarket notification for certain listed Class II clinical toxicology test systems. Before the change, some systems intended for federal drug-testing programs faced an additional 510(k) barrier. Removing that barrier may make it easier for qualifying systems to enter the market, subject to the order’s limitations.
But an FDA 510(k) exemption is not DOT approval. The FDA regulates medical devices; DOT sets the rules for transportation workplace drug testing. The order also does not apply automatically to every test system or collection device. The specific system must fall within the listed device types and meet the applicable conditions.
This distinction matters especially when discussing a hair follicle drug test. The FDA action is not a blanket approval of all hair testing, nor does it authorize hair testing for DOT screens. DOT-regulated testing remains governed by DOT regulations and authorized specimen procedures.
Why DOT employers still cannot use oral fluid testing
DOT rules require operational safeguards that extend beyond the FDA’s device requirements. Under 49 CFR § 40.67(g)(5), employers cannot begin DOT oral-fluid testing until at least two HHS-certified laboratories are available to test oral-fluid specimens. The second lab is needed to support split-specimen testing if a donor requests it.
As of the HHS laboratory list published November 2, 2026, zero laboratories were certified for oral-fluid drug testing. The required threshold is two. Until that condition is met, DOT-regulated employers must continue using the currently available DOT testing method: urine.
The DOT rule adding oral-fluid testing established a framework for its use, but that does not mean employers can put it into practice before the required lab infrastructure is in place.
October 29 guidance: important progress, not a switch-on date
On October 29, HHS published proposed revisions to both the Oral Fluid Mandatory Guidelines and the Urine Mandatory Guidelines.
These notices are proposals, not final revised guidelines. They address operational details such as laboratory certification, quality-control procedures, and other testing procedures. The underlying HHS guidelines already exist; the October notices propose changes to them. They do not certify a laboratory or override DOT’s two-lab requirement.
For employers, the practical takeaway is that the process is moving, but the trigger to begin DOT oral-fluid testing has not occurred.
Fentanyl drug testing in 2026: separate federal and DOT panels
Fentanyl is another issue where it is important to distinguish federal developments from DOT requirements. Fentanyl has been added to the HHS federal drug-testing panel, but it is not currently part of the DOT panel.
DOT’s September 2025 action on fentanyl was a notice of proposed rulemaking, not a final rule. It remains long-term rulemaking. Until DOT issues a final change, the DOT panel remains the standard five drug categories: marijuana, cocaine, amphetamines, opioids, and PCP.
A change to a federal panel does not automatically amend the DOT panel. If your company operates under DOT rules, follow the current DOT requirements and confirm any change through official DOT guidance before updating your policy or testing orders.

What employers can do now
If your workforce is DOT-regulated
Keep your current DOT program aligned with applicable requirements. In particular:
Continue DOT urine testing; do not substitute oral fluid or hair testing for a DOT-mandated test.
Confirm that your collection provider understands DOT procedures and can support the testing you order.
Keep current on the required DOT panel and verify proposed changes before treating them as mandates.
Prepare for a possible future transition by reviewing vendor readiness, policy language, and supervisor and HR training plans.
Preparation is useful, but it should not be confused with authorization. A vendor’s product availability or an FDA exemption alone does not permit DOT use.
If your testing program is non-DOT
Non-DOT employers may consider oral fluid or hair testing under their own workplace policies and applicable law. Before adopting a method, define the purpose of testing, determine which specimen type fits your program, and confirm the laboratory and test system are appropriate for the intended use.
Different specimen types have different collection procedures and detection characteristics. A hair test, for example, is not interchangeable with a DOT urine test. Clear written policies and consistent application help your organization set expectations and support a fair process.

Drug testing Cleveland employers can arrange today
Precision Diagnostic Testing supports employers and individuals with DOT and non-DOT urine drug testing, hair follicle testing, and occupational health screening. Our Cleveland-area location on Shaker Boulevard offers an in-office option for employers and workers in Cleveland, Shaker Heights, Beachwood, Euclid, Bedford, Maple Heights, Cleveland Heights, Parma, Lakewood, and nearby communities.
If you need compliant DOT urine testing, learn more about our DOT and non-DOT urine drug testing services. For non-DOT hair testing, contact us to discuss your requirements and appointment availability.
Appointments are required; we do not accept walk-ins. Please call ahead so our team can confirm the service and scheduling details you need.
The bottom line
The FDA’s October order removed a device-related obstacle for certain test systems. It did not authorize DOT oral-fluid testing, and it did not make hair testing a DOT option. As of early November 2026, no HHS-certified oral-fluid laboratories are listed, while DOT requires at least two before employers can use the method.
For now, DOT employers should keep urine programs current and prepare carefully for potential future changes. Non-DOT employers can evaluate oral-fluid or hair options within their own policy and legal requirements.
To arrange testing or discuss your organization’s needs, contact Precision Diagnostic Testing at 800-484-1641 or info@precisiondiagnostictesting.com. Appointment scheduling is required.

Comments